Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

ALC-0159

From Wikipedia, the free encyclopedia
ALC-0159
Names
Other names
2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide
Identifiers
3D model (JSmol)
ChemSpider
UNII
  • InChI=1S/C33H67NO3/c1-4-6-8-10-12-14-16-18-20-22-24-26-28-34(33(35)32-37-31-30-36-3)29-27-25-23-21-19-17-15-13-11-9-7-5-2/h4-32H2,1-3H3
    Key: BPWFJNQUTKVHIR-UHFFFAOYSA-N
  • CCCCCCCCCCCCCCN(CCCCCCCCCCCCCC)C(=O)COCCOC
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

ALC-0159 is a PEG/lipid conjugate (i.e. PEGylated lipid), specifically, it is the N,N-dimyristylamide of 2-hydroxyacetic acid, O-pegylated to a PEG chain mass of about 2 kilodaltons (corresponding to about 45-46 ethylene oxide units per molecule of N,N-dimyristyl hydroxyacetamide). It is a non-ionic surfactant by its nature. It has been deployed in the Pfizer-BioNTech SARS-CoV-2 mRNA vaccine (0.05 mg per dose)[1] that contains the active ingredient tozinameran.[2]

See also

[edit]
Pfizer–BioNTech COVID-19 vaccine nanoparticle ingredients
Others

References

[edit]
  1. ↑ Schoenmaker, Linde; Witzigmann, Dominik; Kulkarni, Jayesh A.; Verbeke, Rein; Kersten, Gideon; Jiskoot, Wim; Crommelin, Daan J. A. (2021-05-15). "mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability". International Journal of Pharmaceutics. 601 120586. doi:10.1016/j.ijpharm.2021.120586. ISSN 0378-5173. PMC 8032477. PMID 33839230.
  2. ↑ "Public Assessment Report Authorisation for Temporary Supply COVID-19 mRNA Vaccine BNT162b2 (BNT162b2 RNA) concentrate for solution for injection" (PDF). Regulation 174. MHRA. 15 December 2020.